BCL2 and neoplasm: It was also shown that knockdown of HNRNPA2B1 in GBM cells could lead to the inactivation of AKT and STAT3 signaling pathways in tumor cells, reduce the expression of Bcl-2 and PCNA, and thus inhibit the growth of GBM cells, and the establishment of xenograft tumor models using GBM cells with knockdown of HNRNPA2B1 also revealed that knockdown of HNRNPA2B1 could inhibit the progression of GBM in vivo (149).